v3.26.1
Segments (Tables)
 6 Months Ended
Jun. 30, 2026
Segments [Abstract]  
Schedule of Reporting by Segment

Reporting by segment is summarized as follows for the six months ended June 30, 2026 and 2025:

 

Amount in USD   For the six months ended
June 30, 2026		     For the six months ended
June 30, 2025		  
    Biotechnology     Pharmaceutical     Total     Biotechnology     Pharmaceutical     Total  
Revenues   $ -     $ 58,546     $ 58,546     $ -     $ 248,535     $ 248,535  
Gross margin     -       28,303       28,303       -       178,654       178,654  
Operating expenses                                             -  
Depreciation and amortization     5,215       -       5,215       6,491       -       6,491  
Selling, general and administrative     800,254       42,212       842,466       484,740       40,281       525,021  
Research and development     1,106,069       67,059       1,173,128       144,776       25,553       170,329  
Total operating expenses     1,911,538       109,271       2,020,809       636,007       65,834       701,841  
Other expenses                                                
Interest expense     (6,170 )     -       (6,170 )     (111,093 )             (111,093 )
Fair value adjustment     -       -       -       30,511               30,511  
Other income (loss), net     293,472       -       293,472       1,035               1,035  
Other expenses     287,302       -       287,302       (79,547 )     -       (79,547 )
Net income   $ (1,624,236 )   $ (80,968 )   $ (1,705,204 )   $ (715,554 )   $ 112,820     $ (602,734 )
                                                 
Assets of segment   $ 9,174,180     $ 2,181     $ 9,176,361     $ 1,625,477     $ 341     $ 1,625,818  

Reporting by segment is summarized as follows for the three months ended June 30, 2026 and 2025

 

Amount in USD   For the three months ended
June 30, 2026		     For the three months ended
June 30, 2025		  
    Biotechnology     Pharmaceutical     Total     Biotechnology     Pharmaceutical     Total  
Revenues   $ -     $ 26,955     $ 26,955     $ -     $ 49,954     $ 49,954  
Gross margin     -       11,658       11,658       -       24,235       24,235  
Operating expenses                                             -  
Depreciation and amortization     2,610               2,610       2,968       -       2,968  
Selling, general and administrative     341,318       23,573       364,891       248,203       17,192       265,395  
Research and development     469,300       37,423       506,723       69,339       10,722       80,061  
Total Operating expenses     813,228       60,996       874,224       320,510       27,914       348,424  
Other expenses                                                
Interest expense     (3,325 )             (3,325 )     (56,139 )             (56,139 )
Fair value adjustment     -               -       66,519               66,519  
Other income (loss), net     146,208               146,208       5,049               5,049  
Other expenses     142,883       -       142,883       15,429       -       15,429  
Net income   $ (670,345 )   $ (49,338 )   $ (719,683 )   $ (305,081 )   $ (3,679 )   $ (308,760 )
                                                 
Assets of segment   $ 9,174,180     $ 2,181     $ 9,176,361     $ 1,625,477     $ 341     $ 1,625,818  
Schedule of Revenues Revenues for the six months ended June 30, 2026 and 2025 are summarized as follows:

 

    Six months ending
June 30,
2026		     Six months ending
June 30,
2025		  
             
Licensing and milestone fees – Luliconazole   $ -     $ 116,900  
Sale of products     50,285       121,423  
Royalty income related to above product sales     8,261       10,212  
Total   $ 58,546     $ 248,535